Global Times: Ningbo-Zhoushan Port's global connectivity seen from a small button controlling bridge crane

Global Times: Ningbo-Zhoushan Port's global connectivity seen from a small button controlling bridge crane

BEIJING, May 26, 2025 /PRNewswire/ -- When Zhu Shijie started working at the Chuanshan port area of Ningbo-Zhoushan Port in East China's Zhejiang Province in 1999 as a bridge crane operator loading and unloading containers onto or from ships, the...

Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC

Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC

SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from...

World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial

World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial

SUZHOU, China, May 26, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy...

Global Times: Why China's economy so stable despite external challenges?

Global Times: Why China's economy so stable despite external challenges?

BEIJING, May 24, 2025 /PRNewswire/ -- "In April, China's economic data showed resilience despite intensifying external challenges, especially as the exports expanded rapidly. Why is the economy so stable amid external challenges?" This is a question...

Tongcheng Travel 2025Q1 Secures Foothold in the Mass Travel Market Revenue Grows 13.2% Yoy to RMB4.4 Billion

Tongcheng Travel 2025Q1 Secures Foothold in the Mass Travel Market Revenue Grows 13.2% Yoy to RMB4.4 Billion

Rising Travel Spending Boosts Core OTA Business Growth AI Empowers High-Quality Development Across the Travel Industry Chain HONG KONG, May 23, 2025 /PRNewswire/ -- Tongcheng Travel Holdings Limited ("Tongcheng Travel" or the "Company", together...

Eason Technology Limited Receives Notification from NYSE Regarding Delayed Form 20-F Filing

Eason Technology Limited Receives Notification from NYSE Regarding Delayed Form 20-F Filing

HONG KONG, May 23, 2025 /PRNewswire/ -- Eason Technology Limited ("Eason Technology" or the "Company") (NYSE: DXF) today announced that it received a notice from NYSE Regulation indicating that the Company is not in compliance with the continued...

Hisense extends ITS ConnectLife platform to third-party devices via Google's home APIs

Hisense extends ITS ConnectLife platform to third-party devices via Google's home APIs

QINGDAO, China, May 23, 2025 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, announced today the integration of Google's new Home APIs into its ConnectLife app, enabling users to bring their third-party...

Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025

Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025

ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant...

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting

CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the...

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 23, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company...

  • 1
  • ...
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • ...
  • 115
  • menu
    menu